Last reviewed · How we verify
ChAdOx1-S vaccine
ChAdOx1-S is a viral vector vaccine that delivers the SARS-CoV-2 spike protein gene to stimulate adaptive immune responses against COVID-19.
ChAdOx1-S is a viral vector vaccine that delivers the SARS-CoV-2 spike protein gene to stimulate adaptive immune responses against COVID-19. Used for COVID-19 prevention (Phase 3 development).
At a glance
| Generic name | ChAdOx1-S vaccine |
|---|---|
| Sponsor | Vaxxinity, Inc. |
| Drug class | Viral vector vaccine |
| Target | SARS-CoV-2 spike protein |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine uses a replication-deficient chimpanzee adenovirus (ChAdOx1) as a vector to introduce genetic instructions for producing the spike protein of SARS-CoV-2. This triggers both cellular and humoral immune responses, enabling the body to recognize and neutralize the virus upon exposure. The approach leverages established viral vector technology to generate durable immunity without using live virus.
Approved indications
- COVID-19 prevention (Phase 3 development)
Common side effects
- Injection site pain
- Fatigue
- Headache
- Myalgia
- Fever
Key clinical trials
- Phase II/III Study of the AVX/COVID-12 Vaccine Against COVID-19 Applied as a Booster. (PHASE2, PHASE3)
- Phase II Study of AVX/COVID-12 Vaccine in Subjects With Prior SARS-CoV-2 Immunity Evidence (PHASE2)
- Immunogenicity of COVID-19 Vaccines in Tuberculosis Patients
- Mix and Match of the COVID-19 Vaccine for Safety and Immunogenicity (PHASE2)
- Effectiveness of the Oxford-AstraZeneca COVID-19 Vaccine as a 2nd Booster, the REFORCO-Brazil Study
- Immunogenicity and Safety Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine(GBP510) Adjuvanted with AS03 in Adults Aged 18 Years and Older (PHASE3)
- National Cohort Study of Effectiveness and Safety of SARS-CoV-2/COVID-19 Vaccines (ENFORCE) (PHASE4)
- Immunogenicity and Safety Study of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine (GBP510) Adjuvanted With AS03 (COVID-19) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ChAdOx1-S vaccine CI brief — competitive landscape report
- ChAdOx1-S vaccine updates RSS · CI watch RSS
- Vaxxinity, Inc. portfolio CI